Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Up 10.0 %

NASDAQ:BPTH opened at $0.17 on Friday. The business’s 50 day moving average is $0.21 and its two-hundred day moving average is $0.67. Bio-Path has a 52 week low of $0.12 and a 52 week high of $4.57.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.